US2006223881A1PendingUtilityA1
Use of gamma- tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
Individually held — no corporate assignee on recordPriority: Dec 17, 1998Filed: Apr 27, 2006Published: Oct 5, 2006
Est. expiryDec 17, 2018(expired)· nominal 20-yr term from priority
Inventors:William J. Wechter
A61P 9/04A61P 9/08A61P 37/04A61P 43/00A61P 35/00A61P 7/02A61P 9/12A61P 9/00A61P 3/06A61P 9/10A61P 27/02A61P 25/00A61P 1/16A61K 45/06A61K 31/355A61P 13/12A61P 21/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is generally related to the discovery of the therapeutic benefit of administering γ-tocopherol and γ-tocopherol derivatives. More specifically, the use of γ-tocopherol and racemic LLU-α, (S)-LLU-α, or γ-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.
Claims
exact text as granted — not AI-modified1 . A method for treating and/or ameliorating the symptoms of a cerebral ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of a gamma-tocopherol metabolite enriched composition, and by said administering, reducing neuronal damage related to said cerebral ischemic condition.
Join the waitlist — get patent alerts
Track US2006223881A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.